Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
Antimicrob Agents Chemother. Apr 1992; 36(4): 727–732.
PMCID: PMC189373

Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection.


Pirodavir (R77975) is a capsid-binding, antipicornaviral agent with in vitro activity against most rhinovirus (RV) serotypes. We conducted four double-blind, controlled trials to assess the efficacy of intranasal pirodavir in experimentally induced RV infection of susceptible volunteers. Intranasal pirodavir (2 mg per dose) or the hydroxypropyl-beta-cyclodextrin vehicle as a placebo was given by metered pump spray. In three prophylaxis trials, subjects were inoculated with RV within 10 min of the second and third doses. When sprays were given six times per day for a total of 25 doses, infection, detected by either virus shedding or seroconversion, developed in 100% of the 13 placebo-treated subjects and 58% of the 12 pirodavir-treated subjects (P = 0.015). Clinical colds developed in 54% of placebo-treated subjects and 8% of pirodavir-treated subjects during drug administration (efficacy = 85%, P = 0.03), although late-developing colds developed in several subjects in both groups. Significant reductions in morning symptom scores and in the frequency of abnormal middle-ear pressures were also found in the pirodavir group. In contrast, in two prophylaxis studies using three doses daily, no significant antiviral or clinical benefits were observed. When frequent sprays were initiated at 24 h after RV challenge, significant reductions in virus shedding but no clinical benefits were found. Intranasal pirodavir was generally well tolerated but was associated with an excess rate of transient unpleasant taste. The findings indicated that frequent intranasal sprays of pirodavir were effective in preventing experimentally induced RV illness.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • al-Nakib W, Higgins PG, Barrow GI, Tyrrell DA, Andries K, Vanden Bussche G, Taylor N, Janssen PA. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob Agents Chemother. 1989 Apr;33(4):522–525. [PMC free article] [PubMed]
  • Al-Nakib W, Higgins PG, Barrow I, Tyrrell DA, Lenox-Smith I, Ishitsuka H. Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers. J Antimicrob Chemother. 1987 Dec;20(6):887–892. [PubMed]
  • Al-Nakib W, Willman J, Higgins PG, Tyrrell DA, Shepherd WM, Freestone DS. Failure of intranasally administered 4', 6-dichloroflavan to protect against rhinovirus infection in man. Arch Virol. 1987;92(3-4):255–260. [PubMed]
  • Andries K, Dewindt B, De Brabander M, Stokbroekx R, Janssen PA. In vitro activity of R 61837, a new antirhinovirus compound. Arch Virol. 1988;101(3-4):155–167. [PubMed]
  • Andries K, Dewindt B, Snoeks J, Wouters L, Moereels H, Lewi PJ, Janssen PA. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. J Virol. 1990 Mar;64(3):1117–1123. [PMC free article] [PubMed]
  • Dearden C, al-Nakib W, Andries K, Woestenborghs R, Tyrrell DA. Drug resistant rhinoviruses from the nose of experimentally treated volunteers. Arch Virol. 1989;109(1-2):71–81. [PubMed]
  • Hayden FG, Gwaltney JM., Jr Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. J Infect Dis. 1983 Sep;148(3):543–550. [PubMed]
  • McBride TP, Doyle WJ, Hayden FG, Gwaltney JM., Jr Alterations of the eustachian tube, middle ear, and nose in rhinovirus infection. Arch Otolaryngol Head Neck Surg. 1989 Sep;115(9):1054–1059. [PubMed]
  • Otto MJ, Fox MP, Fancher MJ, Kuhrt MF, Diana GD, McKinlay MA. In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1985 Jun;27(6):883–886. [PMC free article] [PubMed]
  • Pevear DC, Fancher MJ, Felock PJ, Rossmann MG, Miller MS, Diana G, Treasurywala AM, McKinlay MA, Dutko FJ. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J Virol. 1989 May;63(5):2002–2007. [PMC free article] [PubMed]
  • Phillpotts RJ, Wallace J, Tyrrell DA, Freestone DS, Shepherd WM. Failure of oral 4',6-dichloroflavan to protect against rhinovirus infection in man. Arch Virol. 1983;75(1-2):115–121. [PubMed]
  • Rossmann MG. The structure of antiviral agents that inhibit uncoating when complexed with viral capsids. Antiviral Res. 1989 Feb;11(1):3–13. [PubMed]
  • Sperber SJ, Hayden FG. Chemotherapy of rhinovirus colds. Antimicrob Agents Chemother. 1988 Apr;32(4):409–419. [PMC free article] [PubMed]
  • Zerial A, Werner GH, Phillpotts RJ, Willmann JS, Higgins PG, Tyrrell DA. Studies on 44 081 R.P., a new antirhinovirus compound, in cell cultures and in volunteers. Antimicrob Agents Chemother. 1985 May;27(5):846–850. [PMC free article] [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • EST
    Published EST sequences
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...